

Redefining the Future of CAR T

Doing What No CAR T Has Done Before

Allogene Corporate Overview January 2025

Legal Disclaimers


This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. To the extent statements contained in this Presentation are not descriptions of historical facts regarding Allogene Therapeutics, Inc. ("Allogene," "we," "us," or "our"), they are forward-looking statements reflecting management's current beliefs and expectations. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels or activity, performance, or achievements to be materially different from those anticipated by such statements. You can identify forwardlooking statements by words such as "could," "designed to," "can," "continue," "estimate," "intend," "intend," "predict," "project," "should," "will," "would" or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in this Presentation include, but are not limited to, statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: ALLOCAR T being highly scalable, off-the-shelf, one time treatments that could leapfrog the competition; ALPHA3 being a pivotal trial; the design of ALPHA3 that ALPHA3 trial could provide the right product to the right patient at the right time; the ability to administer cema-cel in community cancer centers and transform the LBCL market; the potential for cema-cel in earlier line MRD+ settings; the potential to embed cema-cel into first line regimens; use of Foresight Diagnostics test in ALPHA3 and its anticipated sensitivity; the potential for the Foresight CLARITY test to identify MRD+ patients and predict relapse better than scans; that CAR T works more safely and effectively in patients with low disease burden; the potential for cema-cel to improve outcomes in patients; the potential outcomes of ALPHA3; the pace, timing and extent to which we may initiate or enroll patients in our clinical trials or release data from such trials including the ALPHA3, ALLO-329, and TRAVERSE trials; that ALLO-329 will transform the treatment of autoimmune diseases; the timing for the Investigational New Drug relating to ALLO-329 to go into effect; statements related to the market opportunity for our ALPHA3, TRAVERSE, and ALLO-329 programs and our other clinical programs; the potential for ALLO-329 to reset and preserve immunity, and treat autoimmune disorders; the potential for ALLO-316 to be a first- and bestin-class candidate for RCC; statements related to the design and potential benefits of our Dagger® technology including the ability to enhance expansion and persistence of AlloCAR TTM cells and overcome rejection, the expected benefits therefrom, and our plans to deploy the Dagger® technology; the potential for our product candidates to be approved; the potential benefits of AlloCAR T products; the ability of our product candidates to treat various stages and types of cancers including hematological and solid tumors or to treat autoimmune disease; our expectation that our cash runway extends into 2026; the modes of action or the biologic impacts of our product candidates including the engraftment, expansion, persistence and efficacy of allogeneic CAR T cells, the incidence, severity and manageability of side effects of allogeneic CAR T products; the extent to which our clinical trials will support regulatory approval of our product candidates; the potential for off-the-shelf CAR T products; the ability of our manufacturing facility to meet its potential manufacturing capacity; and other statements related to future events or conditions. Various factors may cause material differences between Allogene's expectations and actual results, including, risks and uncertainties related to: changes in the macroeconomic environment or industry that impact our business; competition; risks related to third-party performance; our product candidates are based on novel technologies, which makes it difficult to predict the time and cost of product candidate development and obtaining regulatory approval; the limited nature of the Phase 1 data from our clinical trials and the extent to which such data may or may not be validated in any future clinical trial; our ability to maintain intellectual property rights necessary for the continued development of our product candidates, including pursuant to our license agreements; our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval or limit their commercial potential; the extent to which the Food and Drug Administration disagrees with our clinical or regulatory plans, that our Phase 2 studies are sufficiently designed to be registrational, or the import of our clinical results, which could cause future delays to our clinical trials or regulatory plans, that our Phase 2 studies are sufficiently designed to be registrational, or the import of our clinical results, which could cause future delays to our clinical trials or regulatory plans. may encounter difficulties enrolling patients in our clinical trials; there is no guarantee that Foresight will successfully develop an MRD assay for use as a companion diagnostic with cema-cel, and without a companion diagnostic the prospects for cema-cel could be materially and negatively impacted; we may not be able to demonstrate the safety and efficacy of our product candidates in our clinical trials, which could prevent or delay regulatory approval and commercialization; challenges with manufacturing or optimizing manufacturing of our product candidates or any companion diagnostic for use with our product candidates; and our ability to obtain additional financing to develop our product candidates and implement our operating plans. These and other risks are discussed in greater detail in Allogene's filings with the SEC, including without limitation under the "Risk Factors" heading in its Quarterly Report on Form 10-Q for the guarter ended September 30, 2024. Caution should be exercised when interpreting results from separate trials involving separate product candidates, including comparing Allogene's clinical data to autologous CAR T data. There are differences in the clinical trial design, patient populations, follow-up times, and the product candidates themselves, and the results from the clinical trials of autologous products may have no interpretative value on our existing or future results. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. This Presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or gualification under the securities laws of any such state or jurisdiction.

Clarivate makes no representation or warranty as to the accuracy or completeness of the data ("Clarivate Materials") set forth herein and shall have, and accept, no liability of any kind, whether in contract, tort (including negligence) or otherwise, to any third party arising from or related to use of the Clarivate Materials by Allogene Therapeutics. Any use which Allogene Therapeutics or a third party makes of the Clarivate Materials, or any reliance on it, or decisions to be made based on it, are the sole responsibilities of Client and such third party. In no way shall any data appearing in the Clarivate Materials amount to any form of prediction of future events or circumstances and no such reliance may be inferred or implied.



Unlocking the Future: Developing Single Products into Transformative Platforms

The Platform Opportunities





Dedicated and Scalable CAR T Manufacturing



doses per year capacity (dependent on cell dose)



Quality & Product Characterization

The Process is the Product

Supply Chain Management







A Groundbreaking Trial: The Right Product, The Right Patient, The Right Time



safety and efficacy* in relapses/refractory LBCL

with LBCL who are MRD+ at the completion of front-line R-CHOP **before** disease recurs



The Right Product: Foundational Ph1 Cema-cel Data Paves the Way for ALPHA3

		om Enrollment to $t \le 3 ext{ days}$			
3L Relapsed/Refractory LBCL	All Alloy (n=33)	FCA90 Alloy (n=12)	KYMRIAH^{®1} Phase 2 Pivotal	YESCARTA® ² Phase 2 Pivotal	BREYANZI ^{®3} Phase 2 Pivotal
ORR	58%	67%	50% (label)	72% (label)	73% (label)
CR in LBCL (mITT)	42%	58%	32% (label)	51% (label)	54% (label)
CR at 6 months in LBCL (mITT)	30%	42%	29%	36%	~ 40%
CRS (Gr3+)	0%	0%	22%	13%	4%
Neuro Events (Gr3+)	6%	0%	12%	31%	12%
Infection (Gr3+)	15%	8%	20%	23%	19%
Enrolled who did not receive intended cell product	n=3	n=1***	33%**	9%**	36%^

¹ KYMRIAH USPI and Schuster S et al NEJM 2019. Patient population in the label includes: 78% - primary DLBCL not otherwise specified (NOS); 22% DLBCL following transformation from Follicular Lymphoma

²YES CARTA USPI and Neelapu, NEJM 2017. Patient population in the label includes: 76% - DLBC; 16% - Transformed Follicular Lymphoma; 8% Primary Mediastinal Large B-cell Lymphoma.

³ BREYANZI USPI and Abramson, Lancet, 2020. Patient population in label includes: 53% - de novo DLBCL; 25% DLBCL transformed from indolent Lymphoma; 14% high-grade B-cell Lymphoma; 7% Primary Mediastinal Large B-cell Lymphoma; 1% grade 3B Follicular Lymphoma

**Percent of patients who enrolled and did not receive intended cell product including out of spec products

***After enrollment, one subject was found to have CNS involvement and was excluded

^Percent who underwent lymphodepletion but did not receive intended cell product including out of spec products


FOR ILLUSTRATIVE PURPOSES ONLY: no head-to-head clinical trial has been conducted. Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across studies.

ALPHA/ALPHA2 Data Cutoff Date: April 20, 2023, ICML 2023

The Right Patient: Investigational MRD Assay Identifies MRD+ LBCL Patients

- Detection of Minimal Residual Disease (MRD) after treatment predicts relapse
 - >350 patients assessed across multiple studies
- Data supports the investigational Foresight CLARITY MRD test delivers exquisite clinical performance and may better predict relapse than PET/CT scans
 - Patients who are MRD+ at the end of front-line R-CHOP are >12X more likely to experience disease relapse

Foresight CLARITY™






The Right Time: CAR T Works More Safely & Effectively with Low Disease Burden


Disease Burden and Outcome

Patients with lower tumor volume are more likely to respond while experiencing less neurotoxicity

MRD Allows for Earlier Intervention

Median disease burden is >200-fold lower in patients who are MRD+ at the end of 1L treatment than those who presents with relapse






¹Kurtz, JCO 2018; Alig JCO 2021 Pre 1L: Roschewski et al, ASH 2022 and unpublished Foresight Data; EOT: Roschewski et al, ASH, 2022 and unpublished Foresight Data; Pre 2I: Stepan et al, ASH 2023, 2024

Many patients will not be eligible for CAR T at relapse due to comorbidities or symptom burden, making the end of 1L therapy for patients who are MRD+ the optimal time for CAR T treatment




The Future of CAR T Growth in LBCL is in Community Cancer Centers





ALPHA3 Pivotal Design is Seamless and Efficient



FCA90: Fludarabine 30 mg/m2/day, Cyclophosphamide 300 mg/m2/day, ALLO-647 30 mg/day, administered daily x 3 days FC: Fludarabine 30 mg/m2/day, Cyclophosphamide 300 mg/m2/day, administered daily x 3 days. Cema-cel: 120 million CAR+ cells

Trial Design & Size

Open-label, multicenter, randomized pivotal Phase 2 study

~240 LBCL patients in CR/PR at end of 1L therapy with MRD

~50 academic and community-based cancer centers (US)

Primary Endpoint

EFS per blinded IRC assessment

Secondary Endpoints

PFS per IRC assessment

OS

Rate of conversion to MRD-





Initiated June 2024



Mid-2025: Lymphodepletion selection



1H 2026: Complete Patient Enrollment



YE 2026: Data Readout Primary EFS Analysis



2027: Potential BLA Submission




^a Randomization ratio may be adjusted after the safety interim analysis.

^b Safety and interim efficacy analyses will occur and culminate in LD regimen selection. Patients treated with the selected regimen or followed in observation during

Part A will be included in inferential testing in Part B.

ALPHA3: Potential to Dramatically Transform the LBCL Market



*Source: CAR T class sales projections for US+EU5 markets rounded based on Decision Resources (© 2022 DR/Decision Resources, LLC. All rights reserved. Reproduction, distribution, transmission or publication is prohibited) **Sources: Based on CAR T 2032 class sales projections for US+EU5 markets rounded based on Decision Resources; general net price assumption of \$400K/pt in US based on a utologous CAR T pricing, and ~\$267K/pt in EU5, for illustrative purposes only (Allogene has not made any pricing decisions for any AlloCAR TTM product at this time); adjusted to reflect additional ~\$5B revenue potential for 1L Consolidation market opportunity, with 25% of that eroding 2L CAR T sales and 10% of that eroding 3L+ CAR T sales based on Allogene assessment



Estimated US+EU5 CAR T Net Sales (\$B)

Redefining the Future: Position Cema-cel in Earlier Line MRD+ Settings

Anchor 1L LBCL	Expand B-Cell Malignancies
1L Consolidation LBCL	1L Consolidation Acute Lymphoblastic Leukemia (ALL)
	1L Consolidation Follicular Lymphoma (FL)
	1L Consolidation Mantle Cell Lymphoma (MCL)
	Earlier Line Chronic Lymphocytic Leukemia (CLL) & Small Lymphocytic Lymphoma (SLL)



ALLO-329: Differentiated Profile in a Crowded Autoimmune Disease Field

Dual CD19/CD70 CAR Construct

Overcome Rejection

- Dual CD19/CD70 allogeneic CAR T with Dagger[®] technology, designed to maximize CAR T expansion
- Strong PK/PD effect achievable with Dagger[®] technology may reduce or eliminate the need for lymphodepletion and allow safer use of ALLO-329 in both severe and moderate AID

Address Mechanisms of AID

- ALLO-329 depletes not only CD19+ B cells and plasmablasts, but also CD70+ T and dendritic cells that contribute to maturation and activation of B cells
- Potential to treat autoimmune disorders defined by T cell dysfunction

Reset & Preserve Immunity

- Naïve host B cells reconstitute after treatment
- Spares majority of T cells (CD70-) allowing a quicker immune reconstitution

Key Milestones


Q1 2025: IND



Mid-2025: Phase 1 Trial Initiation




YE 2025: Potential for PoC Clinical Data






Dual Targeting Protects ALLO-329 From Rejection and Potentially Broadens Effect Across Diverse Autoimmune Pathogenesis




Alloreactive CD70+ T Cells



ALLO-329 Depletes Autoreactive B Cells & Autoantibodies from SLE Donors and Shows Resistance to Rejection *In Vivo*





AID Opportunity Has Potential to Greatly Exceed CAR T in Heme Malignancies

Estimated US Diagnosed Prevalence for Select Autoimmune Diseases

Rheumatology	Neurology	Nephrology	Hematology	GI Inflammation
Lupus (SLE) <i>330,000</i>	SPMS / PPMS 200,000	Lupus Nephritis 90,000	Warm Autoimmune Hemolytic Anemia* <i>37,000</i>	Ulcerative Colitis >1,000,000
Systemic Sclerosis 100,000	Myasthenia Gravis 12 <i>4</i> ,000	IgG4 <10,000	Immune Thrombocytopenia* <i>32,000</i>	Crohn's Disease >1,000,000
Myositis <i>70,000</i>	NMOSD <i>15,000</i>		Antiphospholipid Syndrome 168,000	
Rheumatoid Arthritis 725,000	RRMS <i>450,000</i>		Diseases with Clinical PoC for 3-cell Depletion	Scientific Rationale for ALLO-329 (e.g. B- and/or T-cell Driven)

Heme-Onc Global Annual Incidence Across Indications with Approved CAR T ~ 300,000

*Clinical PoC: (1) wAiHA: Shi, CD19 CAR T-Cell Therapy in Refractory Autoimmune Hemolytic Anemia, ASH 2024; (2) ITP: Trautmann-Grill, et al, Salvage treatment of multi-refractory primary Immune thrombocytopenia with CD19 CAR T cells, The Lancet, Jan 2025



ALLO-316: A Potentially First- and Best-In-Class Candidate for RCC

Encouraging Activity In Solid Tumor

TRAVERSE Ph1 Trial Supports Potential in CD70+ RCC

- 50% Overall Response (33% cORR) in heavily pre-treated patients with CD70+ (TPS >50%) expression
- Post-ICI/TKI setting has high unmet need w/current approved product having 22% ORR and <6mo mPFS²

ALLO-316 Has Intrinsic Ability to Overcome Allo-rejection (Dagger[®] Technology)

- Eliminates alloreactive host T cells, leading to robust cell expansion and persistence
- Study advancing with standard FC lymphodepletion regimen

Received FDA RMAT Designation

• In RCC based on TRAVERSE Ph1 clinical data

Key Milestones

Mid-2025: Ongoing Ph1b Data Update

Global Market Opportunity



¹SITC 2024 Data Presentation, ²Welireg (belzutifan) PI

³Epidemiology 2032 projections for G7 markets rounded based on Decision Resources (© 2022 DR/Decision Resources, LLC. All rights reserved. Reproduction, distribution, transmission or publication is prohibited); assumes 80% CD70 expression and 75% of CD70+ with TPS >=50% (Ruf et al., Clin Can Res. 2015).

Market revenue opportunity calculation uses general assumption of \$400 K/patient based on US autologous CAR T pricing for illustrative purposes only; note that Allogene has not made any pricing decisions for any AlloCAR TTM broduct at this time



ALLO-316: Encouraging Activity in Highly Pre-Treated CD70+ RCC Patients


Phase 1 TRAVERSE Trial

Promising Response Rates in Patients with High CD70 Expression

	Patients Evaluable for Disease Outcomes (N=34)								
		CD70							
	All (N=26)	FCA Only (n= 8)	FC Only (n=18)	DL2ª FC500 (Phase 1b) (n=8)	Negative or Unknown (n=8)				
Best overall response, ^b n/N (%)	7/26 (27)	1/8 (13)	6/18 (33)	3/8 (38)	0/8 (0)				
High TPS (≥50) Low TPS (<50)	7/21 (33) 0/5 (0)	1/6 (17) 0/2 (0)	6/15 (40) 0/3 (0)	3/6 (50) 0/2 (0)	_ _				
Confirmed ORR, ^c n/N (%)	5/26 (19)	1/8 (13)	4/18 (22)	2/8 (25)	0/8 (0)				
High TPS (≥50) Low TPS (<50)	5/21 (24) 0/5 (0)	1/6 (17) 0/2 (0)	4/15 (27) 0/3 (0)	2/6 (33) 0/2 (0)					

2 of 6 (33%) patients in the DL2 FC500 cohort with high TPS expression showed durable responses ongoing at \geq 4 months

92% Diseases Control Rate in CD70+ Patients




Of those with TPS ≥50, 76% (16/21) experienced a reduction in tumor burden

Source: SITC/IKCS 2024 Data Presentation, Data cutoff: October 14, 2024.

^a 80 × 10⁶ dose of CD70 CAR+ cells (DL2). ^b Best overall response across visits did not require confirmation for CR/PR or minimum duration for SD. ^c Confirmed best overall response of CR/PR required confirmation at the subsequent visit. CR, complete response; DL, dose level; FC, fludarabine and cyclophosphamide; FC500, fludarabine 30 mg/m² and cyclophosphamide 500 mg/m²; FCA, fludarabine, cyclophosphamide, and ALLO-647; ORR, overall response rate; PR, partial response; TPS, tumor proportion score.



ALLO-316 Demonstrated Robust CAR T Tumor Homing and Cell Expansion



Dagger[®] Technology Spares CD70- T cells



Source: SITC/IKCS 2024 Data Presentation Data cutoff: October 14, 2024. CAR, chimeric antigen receptor; VCN, vector copy number

ALLO-316: AE Profile Appears Consistent with CAR T and Manageable

Phase 1 TRAVERSE Trial

	All Patien	ts (N=39)	DL2 FC50	00 (n=11)
AEs, n (%)	All Grades	Grade ≥3	All Grades	Grade ≥3
CRS	24 (62)	1 (3)	8 (73)	0
Fatigue	23 (59)	1 (3)	2 (18)	0
Neutropenia	22 (56)	20 (51)	7 (64)	7 (64)
Anemia	20 (51)	13 (33)	7 (64)	5 (46)
Nausea	20 (51)	0	3 (27)	0
Thrombocytopenia	18 (46)	10 (26)	7 (64)	3 (27)
Pyrexia	16 (41)	2 (5)	4 (36)	0
AEs of Special Interest	All Grades	Grade ≥3	All Grades	Grade ≥3
Infection Viral infections	24 (62) 13 (33)	12 (31) 2 (5)	5 (46) 2 (18)	2 (18) 0
Neurotoxicity Headache	17 (44) 8 (21)	3 (8) 0	4 (36) 2 (18)	0 0
ICANS	3 (8)	0	3 (27)	0
IEC-HS	5 (13)	1 (3)	2 (18)	0
Graft-vs-host disease	0	0	0	0

• Two DLTs occurred (autoimmune hepatitis and cardiogenic shock)^a in the Flu/Cy/ALLO-647 (FCA) and 80x10⁶ CAR T cells cohort

- Related Grade 5 AEs were cardiogenic shock (DLT), sepsis, and failure to thrive^a
- A protocol-specified algorithm with ruxolitinib was highly effective in abating symptoms of IEC-HS

Source: SITC/IKCS 2024 Data Presentation

20

Data cutoff: October 14, 2024. ^a Please refer to the poster for details. AE, adverse event; CRS, cytokine release syndrome; DL, dose level; DLT, dose-limiting toxicity; FC500, flud arabine 30 mg/m² and cyclophosphamide 500 mg/m²; ICANS, immune effector cell-associated neurotoxicity syndrome; IEC-HS, immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome.



Allogene: Redefining the Future of CAR T



Runway Projected into 2H 2026



2025: Key Year for Pipeline

- cema-cel LD selection
- ALLO-329 clinical PoC
- ALLO-316 Ph1b update

Potential market opportunity

- cema-cel: ~\$5 billion (US+EU5)
- ALLO-329: greater than heme malignancy indications
- ALLO-316: >\$3.5 billion (Global)



THE ONLY COMPETITION IS DISEASE ITSELF



Redefining the Future of CAR T

Allogene's investigational AlloCAR TTM oncology products utilize Cellectis technologies. The anti-CD19 oncology products are developed based on an exclusive license granted by Cellectis to Servier. Servier, which has an exclusive license to the anti-CD19 AlloCAR TTM investigational products from Cellectis, has granted Allogene exclusive rights to these products in the U.S., all EU Member States and the United Kingdom. Allogene has an exclusive license to Cellectis technologies for allogeneic oncology products directed at DLL3 and CD70 for oncology. ALLO-329 (CD19/CD70) in autoimmune disease uses CRISPR gene-editing technology.



Pipeline Designed to Maximize Greatest Opportunity

Target	Program	Trial	Study Population	Discovery	IND- enabling	Phase 1	Phase 2 ¹	Approved	Designation	Status
HEMATO	HEMATOLOGIC MALIGNANCIES									
CD19 (Key Program)	cemacabtagene ansegedleucel (cema-cel)	ALPHA3	LBCL	•						Enrolling
CD70	ALLO-316		CD70+ Heme Malignancies	•	- 🕷					

SOLID TUMORS


CD70 (Key Program)	ALLO-316	TRAVERSE	ccRCC	•			FTD RMAT	Enrolling
CD70	ALLO-316		Other Solid	•	- 🕷			
DLL3	ALLO-213		SCLC	•	-*			
Claudin 18.2	ALLO-182		Gastric & Pancreatic	•	- 🕷			

AUTOIMMUNE DISEASE

CD19/ CD70 (Key Program)	ALLO-329	Rheumatology Disorders	•	IND Submission Q1 2025
--------------------------------	----------	---------------------------	---	---------------------------



Speed and 1x Dose Has Potential to Uniquely Embed Cema-cel into 1L Regimen




1/3 OF PATIENTS EXPERIENCE PROGRESSION WITHIN 12WKS OF COMPLETING 1L THERAPY*

* 1. Tilly H., et al: Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. New England Journal of Medicine. 202



ALPHA3 Addressable Population Creates a ~\$5B Opportunity

1L Consolidation Potential Market Opportunity Sizing¹



¹ Sources: Epidemiology 2032 US and EU5 (France, Germany, Italy, Spain, UK) projections rounded based on Decision Resources (© 2022 DR/Decision Resources, LLC. All rights reserved. Reproduction, distribution, transmission or publication is prohibited), % suitable for observation based on POLARIX study, %MRD+ based on Foresight Diagnostics data, %MRD-tested based on primary market research and advisory board feedback ² Market revenue opportunity calculation uses general net price assumption of \$400K/pt in US based on autologous CAR T pricing, and -\$267K/pt in EU5, for illustrative purposes only; Allogene has not made any pricing decisions for any AlloCAR TTM product at this time



TRAVERSE Addressable Population Creates a >\$3.5B Opportunity

3L+ ccRCC Potential Market Opportunity Sizing



¹Epidemiology 2032 projections for G7 markets rounded based on Decision Resources (© 2022 DR/Decision Resources, LLC. All rights reserved. Reproduction, distribution, transmission or publication is prohibited) ²Flieswasser T, et al. Cancers (Basel) 2019;11:1611

³Market revenue opportunity calculation uses general assumption of \$400 K/patient based on US autologous CAR T pricing for illustrative purposes only; note that Allogene has not made any pricing decisions for any AlloCAR TTM product at this time

